Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on Nirmatrelvir/Ritonavir PK
NCT04962022Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Concentration and Area Under the Plasma Concentration-time Profile From Time Zero to Time Tau. Started Jul 2021; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04962022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04962022.